BAXTER INTL INC shareholders Q3 2020

BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,080 filers reported holding BAXTER INTL INC in Q3 2020. The put-call ratio across all filers is 1.00 and the average weighting 0.2%.

BAXTER INTL INC shareholders Q3 2020
NameSharesValueWeighting ↓
Veritas Asset Management LLP 10,953,932$880,915,0006.12%
GENERATION INVESTMENT MANAGEMENT LLP 11,857,911$953,613,0005.06%
Prosight Management, LP 122,000$9,811,0004.67%
TSFG, LLC 95,627$7,690,0004.57%
Blue Rock Advisors, LLC 63,004$5,070,0004.38%
Unified Trust Company, N.A. 56,386$4,534,0003.22%
Dundas Partners LLP 196,133$15,773,0003.16%
CINCINNATI FINANCIAL CORP 1,284,648$103,311,0003.15%
Eos Focused Equity Management, L.P. 35,349$2,843,0003.04%
Triodos Investment Management BV 183,600$14,765,0003.04%
Sivik Global Healthcare LLC 85,000$6,836,0002.94%
Foyston, Gordon, & Payne Inc 127,851$10,282,0002.65%
OBERMEYER WOOD INVESTMENT COUNSEL, LLLP 431,591$34,709,0002.60%
Cincinnati Specialty Underwriters Insurance CO 61,500$4,946,0002.56%
Progressive Investment Management Corp 80,150$6,446,0002.55%
Locust Wood Capital Advisers 483,745$38,903,0002.51%
PENSIOENFONDS RAIL & OV 1,169,893$94,369,0002.48%
NOESIS CAPITAL MANGEMENT CORP 105,393$8,476,000,0002.40%
Lipe & Dalton 42,886$3,449,0002.40%
Benson Investment Management Company, Inc. 46,315$3,725,0002.39%
About BAXTER INTL INC

Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.

Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.

Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.

Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.

Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

External links

This page lists BAXTER INTL INC's shareholders in Q3 2020. To view BAXTER INTL INC's shareholder history, click here.